We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-8.57%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.15B
AUM Growth
+$16.9M
(+0.54%)
Cap. Flow
-$33.7M
Cap. Flow
% of AUM
-1.07%
Top 10 Holdings %
Top 10 Hldgs %
42.21%
Holding
106
New
27
Increased
26
Reduced
18
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
|
+$103M |
| 2 |
Viatris
VTRS
|
+$76.6M |
| 3 |
Pacira BioSciences
PCRX
|
+$67.6M |
| 4 |
Brookdale Senior Living
BKD
|
+$65.1M |
| 5 |
ABMD
Abiomed Inc
ABMD
|
+$62.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLRN
Acceleron Pharma
XLRN
|
+$79.8M |
| 2 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
+$71.3M |
| 3 |
Tandem Diabetes Care
TNDM
|
+$66.5M |
| 4 |
Humana
HUM
|
+$30.1M |
| 5 |
BOLD
Audentes Therapeutics, Inc
BOLD
|
+$29.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.83% |
| 2 | Technology | 0.07% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
AdaptHealth
AHCO
$1.46B
| $275M | 8.73% |
17,199,888
| – | – |
|
|
2
Viatris
VTRS
$20.1B
| $181M | 5.75% |
12,151,362
+3,999,608
| +49% | +$76.6M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $174M | 5.54% |
5,888,511
+1,146,200
| +24% | +$38.8M |
|
|
DFPHU
4
DELISTED
DFP Healthcare Acquisitions Corp. Unit
DFPHU
| $103M | 3.27% |
+10,460,000
| New | +$103M |
|
5
Centene
CNC
$31.3B
| $75.3M | 2.39% |
1,267,206
+158,806
| +14% | +$9.64M |
|
|
ORTX
6
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $66.7M | 2.12% |
886,225
| – | – |
|
7
Q32 Bio
QTTB
$450M
| $62.7M | 1.99% |
224,295
-67,129
| -23% | -$20.6M |
|
8
Schrodinger
SDGR
$1.12B
| $58M | 1.84% |
+1,346,167
| New | +$50.8M |
|
|
9
Brookdale Senior Living
BKD
$3.62B
| $57.4M | 1.82% |
18,402,355
+11,178,936
| +155% | +$65.1M |
|
|
IMMU
10
DELISTED
Immunomedics Inc
IMMU
| $55.4M | 1.76% |
4,107,464
+2,384,846
| +138% | +$40.1M |
|
|
ABMD
11
DELISTED
Abiomed Inc
ABMD
| $54.6M | 1.73% |
+376,000
| New | +$62.4M |
|
|
12
Pacira BioSciences
PCRX
$1.02B
| $54.6M | 1.73% |
+1,627,521
| New | +$67.6M |
|
13
Arvinas
ARVN
$518M
| $48.9M | 1.55% |
1,212,922
+124,688
| +11% | +$5.83M |
|
14
Mirum Pharmaceuticals
MIRM
$6.89B
| $48.3M | 1.53% |
3,448,912
| – | – |
|
15
Rhythm Pharmaceuticals
RYTM
$7B
| $46.1M | 1.46% |
3,031,565
-1,257,726
| -29% | -$22.5M |
|
|
AXNX
16
DELISTED
Axonics, Inc. Common Stock
AXNX
| $45.6M | 1.45% |
1,794,594
+956,649
| +114% | +$28.4M |
|
|
SILK
17
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $42.4M | 1.35% |
1,348,000
+68,520
| +5% | +$2.74M |
|
18
Alector
ALEC
$164M
| $42M | 1.33% |
1,738,997
-337,815
| -16% | -$8.61M |
|
19
Vericel Corp
VCEL
$2.3B
| $40.8M | 1.29% |
4,447,109
+1,699,546
| +62% | +$25.5M |
|
20
Revolution Medicines
RVMD
$40.2B
| $39.4M | 1.25% |
+1,796,383
| New | +$49.7M |
|
21
Natera
NTRA
$37.5B
| $39.3M | 1.25% |
+1,316,000
| New | +$44M |
|
22
Fate Therapeutics
FATE
$281M
| $35.9M | 1.14% |
1,616,993
-385,612
| -19% | -$9.75M |
|
|
AERI
23
DELISTED
Aerie Pharmaceuticals
AERI
| $34.2M | 1.08% |
2,532,147
+759,892
| +43% | +$14.4M |
|
|
XENT
24
DELISTED
Intersect ENT, Inc
XENT
| $32.7M | 1.04% |
2,758,267
-38,766
| -1% | -$859K |
|
|
XLRN
25
DELISTED
Acceleron Pharma
XLRN
| $30.8M | 0.98% |
343,000
-1,026,625
| -75% | -$79.8M |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q1 2020 Portfolio in Review
As of Q1 2020, Deerfield Management held 106 positions worth $3.15B, up 0.54% from $3.13B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deerfield Management's Q1 2020 filing shows 27 new, 26 increased, 18 reduced and 18 closed positions. Its largest new stake was DFP Healthcare Acquisitions Corp. Unit: 10,460,000 shares worth $103M. The largest sale was Acceleron Pharma, an estimated $79.8M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 78% a quarter earlier, followed by Technology and Financials.
- Deerfield Management's largest Q1 2020 buy was DFP Healthcare Acquisitions Corp. Unit: 10,460,000 shares worth $103M.
- Deerfield Management added most to Viatris in Q1 2020, an estimated $76.6M increase.
- Deerfield Management's biggest Q1 2020 reduction was Acceleron Pharma, cutting an estimated $79.8M.
- Deerfield Management fully exited Ra Pharmaceuticals, Inc. Common Stock in Q1 2020, selling an estimated $71.3M.
- Deerfield Management's ten largest holdings make up 42% of its $3.15B portfolio in Q1 2020.
- Deerfield Management opened 27 new positions and closed 18 in Q1 2020.
- Deerfield Management's portfolio value rose 0.54% quarter-over-quarter to $3.15B.
Based on Deerfield Management's 13F filing for Q1 2020, filed 15 May 2020.